Federal Judge Orders FDA to Reconsider Mifepristone Prescribing Restrictions

Jul 24, 2026

On July 23, 2026, U.S. District Judge Robert S. Ballou ruled that the FDA's 2023 restrictions requiring special certification for prescribing mifepristone were unlawful. The ruling ordered the agency to reconsider these rules, noting mifepristone's established safety record. This decision comes amid escalating legal battles, including a pending Fifth Circuit case where Louisiana seeks to ban abortion pills by mail, a method that accounted for 30% of all U.S. abortions in 2025.

Federal Court Mifepristone Ruling

▪The Center for Reproductive Rights filed the lawsuit challenging the mifepristone restrictions in May 2023 on behalf of abortion providers in Virginia, Kansas, and Montana.
▪U.S. District Judge Robert S. Ballou ordered the U.S. Food and Drug Administration to reconsider its 2023 mifepristone regulations.
▪On July 23, 2026, U.S. District Judge Robert S. Ballou ruled that the U.S. Food and Drug Administration's restrictions on mifepristone were unlawful.

Mifepristone Safety Scientific Evidence

▪U.S. District Judge Robert S. Ballou stated the U.S. Food and Drug Administration failed to explain how prescribing mifepristone without restrictions creates an intolerable risk.
▪The U.S. Food and Drug Administration initially approved mifepristone in 2000 and has repeatedly affirmed the drug's safety and effectiveness.

FDA Certification Registration Requirements

▪The challenged U.S. Food and Drug Administration regulations require patients to sign duplicative, inaccurate, and confusing paperwork to obtain mifepristone.
▪The 2023 U.S. Food and Drug Administration rule required healthcare providers and pharmacies to obtain special certification to prescribe or dispense mifepristone.

Fifth Circuit Louisiana Case

▪More than 400 state lawmakers signed an amicus brief submitted to the Fifth Circuit Court of Appeals in the Louisiana v. FDA case.
▪Louisiana is seeking to reinstate in-person dispensing requirements and ban the mailing of mifepristone.

Medication Abortion Usage Rates

▪Medication abortion using mifepristone accounts for more than 60% of all abortions in the United States.
▪Telehealth abortion care, or abortion pills by mail, accounted for approximately 30% of all abortions in the United States in 2025.